Page 2 - Antiviral Program News Today

The University of Minnesota has received $66 million from the National Institute of Allergy and Infectious Diseases to establish a center to develop antiviral drugs for pandemic-level viruses, including SARS-CoV-2.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

The new center will develop antivirals that could combat future pandemic-level viruses.

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

BOSTON, May 18, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National

/PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration...

BOSTON, May 18, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today

/PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration...

By Riley Griffin & Josh Wingrove In its quest to build up its stockpile of Covid-19 drugs, the US government has held talks with Japanese drugmaker Shionogi & Co. about buying its experimental antiviral pill, people familiar with the matter said. Finding the money to pay for it could be…

Shionogi's treatment is in late-stage clinical trials and hasn’t yet been authorized, but in earlier studies, it reduced viral loads in patients within the first few days of use.